DrugPatentWatch Database Preview

Pfizer Company Profile

Email this page to a colleague

PFIZER has one hundred and thirty-five approved drugs.

There are thirty-six US patents protecting PFIZER drugs. There is one tentative approval on PFIZER drugs.

There are seven hundred and sixty-six patent family members on PFIZER drugs in seventy-one countries and one hundred and forty-six supplementary protection certificates in seventeen countries.

International Patents:	766
US Patents:	36
Tradenames:	102
Ingredients:	96
NDAs:	135
Drug Master File Entries:	3
Patent Litigation for Pfizer:	See patent lawsuits for Pfizer
PTAB Cases with Pfizer as petitioner:	See PTAB cases with Pfizer as petitioner

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer Inc	XELJANZ XR	tofacitinib citrate	TABLET, EXTENDED RELEASE;ORAL	208246-002	Dec 12, 2019		RX	Yes	No	7,301,023	Start Trial		Y		Start Trial
Pfizer	TROVAN PRESERVATIVE FREE	alatrofloxacin mesylate	INJECTABLE;INJECTION	020760-001	Dec 18, 1997		DISCN	No	No		Start Trial				Start Trial
Pfizer	NEOBIOTIC	neomycin sulfate	TABLET;ORAL	060475-001	Approved Prior to Jan 1, 1982		DISCN	No	No		Start Trial				Start Trial
Pfizer Inc	IBRANCE	palbociclib	TABLET;ORAL	212436-002	Nov 1, 2019		RX	Yes	No	7,456,168	Start Trial				Start Trial
Pfizer	ATARAX	hydroxyzine hydrochloride	TABLET;ORAL	010392-005	Approved Prior to Jan 1, 1982		DISCN	Yes	No		Start Trial				Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer Pharms	NEURONTIN	gabapentin	TABLET;ORAL	020882-002	Oct 9, 1998	5,084,479*PED	Start Trial
Pfizer	DIFLUCAN IN SODIUM CHLORIDE 0.9%	fluconazole	INJECTABLE;INJECTION	019950-001	Jan 29, 1990	4,416,682	Start Trial
Pfizer Pharms	ACCUPRIL	quinapril hydrochloride	TABLET;ORAL	019885-003	Nov 19, 1991	5,684,016*PED	Start Trial
Pfizer	CADUET	amlodipine besylate; atorvastatin calcium	TABLET;ORAL	021540-006	Jan 30, 2004	RE40667*PED	Start Trial
Pfizer	MINIPRESS	prazosin hydrochloride	CAPSULE;ORAL	017442-001	Approved Prior to Jan 1, 1982	4,130,647	Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Tablets	100 mg	➤ Subscribe	2004-10-25
➤ Subscribe	Sublingual Tablets	0.3 mg, 0.4 mg and 0.6 mg	➤ Subscribe	2005-10-19
➤ Subscribe	Capsules	20 mg, 40 mg, 60 mg and 80 mg	➤ Subscribe	2005-02-07
➤ Subscribe	Capsules	0.125 mg, 0.25 mg, and 0.5 mg	➤ Subscribe	2014-05-01
➤ Subscribe	Tablets	150 mg and 200 mg	➤ Subscribe	2005-11-09
➤ Subscribe	Tablets	5 mg/10 mg, 5 mg/20 mg, 5 mg/40 mg, 10 mg/10 mg, 10 mg/20 mg and 10 mg/80 mg	➤ Subscribe	2006-12-29
➤ Subscribe	Tablets	2.5 mg/40 mg	➤ Subscribe	2009-09-17
➤ Subscribe	Injection	20 mg/mL, 2 mL and 5 mL vials	➤ Subscribe	2004-07-26
➤ Subscribe	Tablets	25 mg and 50 mg	➤ Subscribe	2004-11-19
➤ Subscribe	Tablets	20 mg and 40 mg	➤ Subscribe	2010-03-29
➤ Subscribe	Sublingual Tablets	0.6 mg	➤ Subscribe	2011-12-29
➤ Subscribe	Capsules	5 mg and 10 mg	➤ Subscribe	2005-06-21
➤ Subscribe	For Injection	500 mg/vial	➤ Subscribe	2011-06-17
➤ Subscribe	Extended-release Tablets	4 mg and 8 mg	➤ Subscribe	2012-10-31
➤ Subscribe	Tablets	5 mg/80 mg	➤ Subscribe	2009-04-07
➤ Subscribe	Capsules	75 mg, 100 mg and 125 mg	➤ Subscribe	2019-02-04
➤ Subscribe	Extended-release Tablets	11 mg	➤ Subscribe	2016-11-07

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1746999	2019C/540	Belgium	Start Trial	PRODUCT NAME: DACOMITINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT HIERVAN; AUTHORISATION NUMBER AND DATE: EU/1/19/1354 20190404
1746999	1990044-8	Sweden	Start Trial	PRODUCT NAME: DACOMITINIB OR APHARMACEUTICAL ACCEPTABLE SALT THEROF; REG. NO/DATE: EU/1/19/1354 20190404
1507558	12C0033	France	Start Trial	PRODUCT NAME: ALISKIRENE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE E CELUI-CI, AMLODIPINE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, ET HYDROCHLOROTHIAZIDE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; NAT. REGISTRATION NO/DATE: EU/1/11/730/001 20111122; FIRST REGISTRATION: 6167801 20110705
1746976	1790033-3	Sweden	Start Trial	PRODUCT NAME: IRINOTECAN SUCROSOFATE SALT.; REG. NO/DATE: EU/1/16/1130 20161008
1003503	30/2006	Austria	Start Trial	PRODUCT NAME: AMLODIPIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SAEUREADDITIONSALZ DESSELBEN IN KOMBINATION MIT ATORVASTATIN ODER EINEM PHARMAZEUTISCH ANNEHMBAREN SALZ DESSELBEN; NAT. REGISTRATION NO/DATE: 1-26271, 1-26273 20060330; FIRST REGISTRATION: FR 369300.9;369301.5; 369302.1;369303.8;369304.4;369305.0; 20050707
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.